Evidence map›Paper›PMID 41591979›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.

Sara-Jayne Thursby, Zhicheng Jin, Jacob Blum, Andrei Gurau, Michaël Noë, Robert B Scharpf, Victor E Velculescu, Leslie Cope, Malcolm Brock, Stephen Baylin and 2 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sara-Jayne ThursbyDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0001-6533-2415
Zhicheng JinDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0009-8825-1464
Jacob BlumDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-0140-5555
Andrei GurauDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4610-721X
Michaël NoëDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5336-4508
Robert B ScharpfDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4702-2656
Victor E VelculescuDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1195-438X
Leslie CopeDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4098-3289
Malcolm BrockDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-2961-851X
Stephen BaylinDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3697-3798
Thomas PisanicDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0001-5796-0836
Hariharan EaswaranDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5517-2972

Funding

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)National Cancer Institute (NCI) P30CA006973National Cancer Institute (NCI) R01CA229240National Cancer Institute (NCI) R01CA230995National Institute of Environmental Health Sciences (DEHS) R01ES011858National Institute on Aging (NIA) U01AG066101Samuel Waxman Cancer Research Foundation (SWCRF) Collaboration for a Cure GrantThe Commonwealth FoundationThe Evelyn Grollman Glick Scholar AwardThe Schnabl Charitable Fund
6 · The paper itself

Abstract

purposeCancers present significant DNA methylation changes, which arise in a stochastic manner, marked by extensive epigenetic variation, indicative of high epigenetic instability. We aimed to evaluate the utility of epigenetic instability for cell-free DNA (cfDNA)-based cancer detection. EXPERIMENTAL

designThrough analysis of cancer DNA methylation datasets (n = 2,084), we identified a set of 269 CpG island regions that robustly captures this instability in a cancer-specific manner. We developed metrics to measure this epigenetic instability, termed the epigenetic instability index (EII), for cancer screening via cfDNA methylation.

resultsMachine learning classifiers using the EII of these 269 regions efficiently identified breast and lung cancers from cfDNA, differentiating even stage IA lung adenocarcinoma with ∼81% sensitivity and early-stage breast cancer with ∼68% sensitivity, both at 95% specificity.

conclusionsOur studies demonstrate that quantifying epigenetic instability is a novel, capable approach to distinguishing cancer from normal cases using cfDNA, performing better than standard approaches using absolute methylation changes. The epigenetic instability-based approaches for cancer detection developed here, along with their validation in independent datasets, support further development and the potential for future clinical application of these strategies in cancer screening.

Indexed as

Biomarkers, TumorBreast NeoplasmsCell-Free Nucleic AcidsEarly Detection of CancerEpigenesis, GeneticGenomic InstabilityLung NeoplasmsNeoplasmsCpG IslandsDNA MethylationFemaleHumansMachine LearningBiomarkers, TumorCell-Free Nucleic Acids

Identifiers

PMID41591979
PMCPMC13080316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.